Business
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
--Upon issuance, patent will be the fourth Japanese patent to issue for the ThermoStem® program targeting obesity and metabolic disorders, including type 2
About this update from Biorestorative Therapies, Inc.
[{"type":"text","content":"--Upon issuance, patent will be the fourth Japanese patent to issue for the ThermoStem® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., May 15, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the Japanese Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program. The notice of allowance was issued on May 8, 2023. Upon issuance, this will be the fourth patent granted in Japan for the ThermoStem® program. Claims granted under the new Japanese patent will cover implantable three-dimensional scaffolds and brown adipocytes that have been derived from human brown adipose (fat)-derived stem cells. Therapeutic benefits of using brown adipose have been demonstrated in various models and may provide a valuable therapeutic tool for treating a range of metabolic disorders. “This is the third notice of allowance we have received regarding our ThermoStem® program in 2023. This notice of allowance is very meaningful as it provides the Company with further protection and strengthens our technology in key markets as we develop and expand into the clinic. Additionally, it enhances our ability to engage with the strategic community on collaborative and partnering opportunities,” said Lance Alstodt, the Company’s CEO. About BioRestorative Therapies, Inc. BioRestorative Therapies, Inc. ( www.biorestorative.com ) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopres...